Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Viveve Medical Inc (NQ: VIVE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Viveve Medical Inc

< Previous 1 2 Next >
Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
Via ACCESSWIRE
Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded
Via ACCESSWIRE
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
Via ACCESSWIRE
InvestorNewsBreaks — Viveve Medical Inc. (NASDAQ: VIVE) Releases Q3 2022 Financial Report, Corporate Update
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
Via ACCESSWIRE
Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022
Via ACCESSWIRE
Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout
Via ACCESSWIRE
Viveve to Participate in Ladenburg Thalmann Healthcare Conference
Via ACCESSWIRE
Viveve to Participate in Alliance Global Partners Virtual MedTech Conference
Via ACCESSWIRE
Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
Viveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022
Via ACCESSWIRE
Viveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022
ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today... 
From Viveve Medical, Inc.
Via AccessWire
Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan
ENGLEWOOD, CO / ACCESSWIRE / July 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today... 
From Viveve Medical, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Viveve to Participate in H.C. Wainwright Global Investment Conference
ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will... 
From Viveve Medical, Inc.
Via AccessWire
Viveve CEO Scott Durbin Named Among Top 50 Healthcare Technology Leaders of 2022 by Healthcare Technology Report
Durbin recognized for second consecutive year for leading development of Viveve's innovative technology for treatment of stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 /... 
From Viveve Medical, Inc.
Via AccessWire
Viveve Reports First Quarter 2022 Financial Results and Provides Corporate Update
Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET... 
From Viveve Medical, Inc.
Via AccessWire
Viveve to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 12, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Viveve Medical, Inc.
Via AccessWire
Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update
Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post... 
From Viveve Medical, Inc.
Via AccessWire
Viveve to Report Full Year 2021 Financial Results and Provide Corporate Update on March 17, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021... 
From Viveve Medical, Inc.
Via AccessWire
Healthcare Technology Report Names Viveve Regulatory Executive Among Top 25 Women Leaders in Medical Devices
Viveve SVP Suzon Lommel named to list for second consecutive year for efforts to advance innovative technologies to treat stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / January 13,... 
From Viveve Medical, Inc.
Via AccessWire
Viveve to Participate in H.C. Wainwright BIOCONNECT Conference
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer,... 
From Viveve Medical, Inc.
Via AccessWire
Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence
Major milestone achieved in Company's advance toward a new U.S. SUI indication ENGLEWOOD, CO / ACCESSWIRE / December 14, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused... 
From Viveve Medical, Inc.
Via AccessWire
Exposures Product Safety
Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Total revenue of $1.6M reported for Q3 - Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4 ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve... 
From Viveve Medical, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Viveve to Host Conference Call on November 11, 2021 to Report Third Quarter Financial Results and Provide Corporate Update
ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third... 
From Viveve Medical, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Viveve Announces Issuance of New Device and Methods Patent in U.S
Issuance further expands and strengthens Company's intellectual property portfolio ENGLEWOOD, CO / ACCESSWIRE / October 28, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company... 
From Viveve Medical, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia
Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Viveve Medical, Inc.... 
From Viveve Medical, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive... 
From Viveve Medical, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Total revenue of $1.7M reported for Q2 Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarter Pivotal SUI PURSUIT trial enrollment on-track for... 
From Viveve Medical, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.